- 英文名称
- (2-Chloro-4-phenoxyphenyl)(4-(((3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methanone
- 分子式
- C25H23ClN4O4
- 分子量
- 478.93
- 中文别名
- ARQ 531; ARQ 531; nemtabrutinib; ARQ-531; MK-1026; JTZ51LIXN4; ARQ531; (2-Chloro-4-phenoxyphenyl)(4-(((3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)-7h-pyrrolo[2,3-d]pyrimidin-5-yl)methanone; (2-chloro-4-phenoxyphenyl)-[4-[[(3R,6S)-6-(hydroxymethyl)oxan-3-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]methanone; (2-Chloro-4-phenoxyphenyl)(4-(((3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)methanone; (2-chloro-4-phenoxyphenyl)-(4-(((3R,6S)-6-(hydroxymethyl)oxan-3-yl)amino)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)methanone; RefChem:165056; BTK Inhibitor ARQ 531; Bruton's Tyrosine Kinase Inhibitor ARQ 531; 880-144-6; MFCD31692379; (2-Chloro-4-phenoxyphenyl)(4-(((3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methanone; MK1026; 1,5-Anhydro-2-[[5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-2,3,4-trideoxy-D-erythro-hexitol; 1,5-anhydro-2-{[5-(2-chloro-4-phenoxybenzene-1-carbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}-2,3,4-trideoxy-D-erythro-hexitol; [(2S,5R)-5-{[5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}oxan-2-yl]methanol; 1,5-Anhydro-2-{[5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}-2,3,4-trideoxy-D-erythro-hexitol; ArQule 531; UNII-JTZ51LIXN4; NEMTABRUTINIB [INN]; Nemtabrutinib (USAN/INN); NEMTABRUTINIB [USAN]; C25H23ClN4O4; NEMTABRUTINIB [WHO-DD]; orb1308638; CHEMBL4756476; SCHEMBL18756744; SCHEMBL18770934; SCHEMBL29393386; SCHEMBL29564591; GTPL11413; BDBM499811; DTXSID001381948; GLXC-21845; EX-A2727; VID39315; NSC830201; s8711; AKOS040741165; AT10312; CCG-269533; NSC-830201; US11020398, Compound I-123; AC-36883; AS-79762; DA-50714; HY-112215; CS-0044154; D12504; T14323; (13R,16S)-52-chloro-16-(hydroxymethyl)-37H-6-oxa-2-aza-3(4,5)-pyrrolo[2,3-d]pyrimidina-1(3)oxana-5(1,4),7(1)dibenzenaheptaphan-4-one; (2-chloro-4-phenoxy-phenyl)-[4-[[(3R,6S)-6-(hydroxymethyl)tetrahydropyran-3-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]methanone; D-erythro-Hexitol, 1,5-anhydro-2-[[5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-2,3,4-trideoxy-; HRA
- 用途
- 化学合成；作为 BTK 可逆的、非共价的、具有口服活性的抑制剂，对 WT-BTK 和 C481S-BTK 的 IC50 值分别为 0.85 nM 和 0.39 nM。
